As reports of adverse events from commonly used drugs continue to come to public attention, critics have stepped up demands for new and improved postmarket surveillance efforts.
While the US Food and Drug Administration (FDA) is rethinking its policies, independent “pharmacovigilance” endeavors are performing their own analyses and sounding alarms about potential dangers of numerous prescription drugs. Investigators in one program, called Research on Adverse Drug Events and Reports (RADAR), hope to improve patient safety through earlier detection of serious adverse drug reactions.
Hampton T. Postmarket “Pharmacovigilance” Program on Alert for Adverse Events From Drugs. JAMA. 2007;298(8):851-852. doi:10.1001/jama.298.8.851